ÂÜÀòÂÒÂ×

Daniel Gil is a veteran leader in Pharmaceutical R&D, specializing in early drug development. He is currently a Board member of Cell Care, as well as Founder of CELLerity Consulting and CEO of Pelage Pharmaceuticals. In his 30+ year career at Allergan, which ended in 2018, he led drug research and early-stage clinical development in the areas of Ophthalmology, Neuroscience, and Dermatology. He elevated 13 drug candidates into clinical development, directed 8 clinical development teams, and oversaw clinical studies ranging from translational to phase 2 proof-of-concept stages. Most recently, he served as Co-chair of Early Stage Governance Board that oversaw pre-POC clinical development across therapeutic areas; Chair of Research Portfolio Committee that oversaw progression of the research portfolio; Director of a research group that included Medicinal Chemistry, Biologics, and translational pharmacology. At Allergan, he directed several biotech partnerships including one with Acadia Pharmaceuticals. He is an inventor on more than 70 issued US patents and author of 42 peer-reviewed research articles. Dr. Gil has an undergraduate degree in Biology from Harvard and a Ph.D. in Pharmacology from the University of Pennsylvania.